About: Tocilizumab, a potent interleukin-6 receptor inhibitor, decreases bone resorption and increases the rate of bacterial infection after tooth extraction in rats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab, a potent interleukin-6 receptor inhibitor, decreases bone resorption and increases the rate of bacterial infection after tooth extraction in rats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tocilizumab, a potent interleukin-6 receptor inhibitor, decreases bone resorption and increases the rate of bacterial infection after tooth extraction in rats
Creator	Paula, Ana Martins, Lima Aec, Alves, Nunes Ap, Bitú Sousa, Fabrício De Barros, J De Queiroz Rodrigues, Maria Ernando, Antônio Fb, Mota Ferreira Júnior, Carlos Ferreira, Carlos Ferreira, Júnior Goberlânio De Barros Silva, Paulo Goberlânio De Barros, Paulo Imaculada De Queiroz Rodrigues, Maria Lima, Verde Meq, Sousa Mota, Lima Mrl, Negreiros Negreiros, Ana Nunes, Alves Nunes, Negreiros Ohana, Joyce Pg, Silva Quezado, Maria Rogério, Mário Sousa, Bitú Tocilizumab, Verde, Lima
Source	Elsevier; PMC
abstract	PURPOSE: Our objective was to evaluate the influence of pre-treatment with tocilizumab (TCZ) in bone healing after tooth extraction in rats. METHODS: Wistar male rats were equally divided into sham (i.e., non-operated), saline (both treated with 0.1 ml/kg saline), and six TCZ groups treated with 1, 2, 4, 8, 16, and 32 mg/kg TCZ (TCZ1 to TCZ32, respectively). Twenty-four hours after administration of vehicle or TCZ, exodontia of the first lower left molar was performed, and the animals were euthanized three days later for hematological analysis and organ (liver, spleen, and kidney mass indexes, and histological evaluation), gingiva (myeloperoxidase [MPO] assay), and mandible (radiographic, histomorphometric analysis, and IL-6 immunostaining) evaluation. Analysis of variance/Bonferroni test (statistical significance, p<0.05) was performed using GraphPad Prism version 5.0 (GraphPad Inc, San Diego, CA, USA). RESULTS: There was no difference in radiographic results; however, leukopenia (p=0.039) and neutropenia (p<0.001) were statistically significant in the TCZ16 and TCZ32 groups. Weight loss (p<0.001) and reduced liver index (p=0.001) were significantly dose dependent; however, no histological alterations were observed in the other organs. Osteoclast counts were reduced in groups TCZ4 to TCZ32 (p<0.001), and IL-6 immunostaining increased in the TCZ8 to TCZ32 groups (p<0.001). Alveolar infection rates increased in groups TCZ4 to TCZ32 (p<0.001), and MPO had biphasic response, exhibiting a reduction in groups TCZ2 and TCZ4, and an increase in group TCZ32 (p=0.004). CONCLUSION: TCZ-induced immunosuppression led to a reduction in osteoclast function, an increase in alveolar infection, and compensatory neutrophil infiltration.
has issue date	2020-08-15(xsd:dateTime)
bibo:doi	10.1016/j.joms.2020.08.012
has license	no-cc
sha1sum (hex)	fe8c1413d57545aabdfe09f9d69a4d3a7652da4d
schema:url	https://doi.org/10.1016/j.joms.2020.08.012
resource representing a document's title	Tocilizumab, a potent interleukin-6 receptor inhibitor, decreases bone resorption and increases the rate of bacterial infection after tooth extraction in rats
has PubMed Central identifier	PMC7428756
schema:publication	J Oral Maxillofac Surg
resource representing a document's body	covid:fe8c1413d57545aabdfe09f9d69a4d3a7652da4d#body_text
is schema:about of	named entity 'Journal' named entity 'tooth extraction' named entity 'inhibitor' named entity 'inhibitor' named entity 'HTTPS' named entity 'N A' named entity 'https' named entity 'bone resorption' named entity 'interleukin' named entity 'Tocilizumab' named entity 'inhibits' named entity 'yahoo.com' named entity 'bacterial infection' named entity 'Tocilizumab' named entity 'exodontia' named entity 'interleukin-6 receptor' named entity 'tooth extraction' named entity 'Tocilizumab' named entity 'H2O2' named entity 'control group' named entity 'IL-6' named entity 'euthanization' named entity 'hepatocytes' named entity 'light microscope' named entity 'osteoclast' named entity 'experimental models' named entity 'COVID-19 pandemic' named entity 'hydrogen peroxide' named entity 'paraffin block' named entity 'TNF-α' named entity 'physiological processes' named entity 'assay' named entity 'cytokine' named entity 'ketamine' named entity 'osteoclast' named entity 'sham surgery' named entity 'statistical significance' named entity 'experimental groups' named entity 'monoclonal antibody' named entity 'macrophage activation' named entity '0.9' named entity 'IL-1β' named entity 'Hepatotoxicity' named entity 'alveolar bone' named entity 'tumor necrosis factor alpha' named entity 'IL-6' named entity 'critically ill patients' named entity 'IL-6R' named entity 'osteomyelitis' named entity 'monoclonal antibody' named entity 'precision balance' named entity 'dose dependent' named entity 'Neutrophils' named entity 'Korea'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software